Long-term follow-data shows Revuforj to be effective in the treatment patients with R/R KMT2Ar acute leukemias.
The disgraced film producer was diagnosed with leukaemia in November. Now his lawyer has confirmed that the 72-year-old was ...
Johnson & Johnson announced new frontline data featuring TECVAYLI from two investigational studies in patients with newly ...
Genmab A/S (GMAB) announced new results from the Phase 1b/2 EPCORE NHL-2 trial evaluating fixed-duration epcoritamab, a T-cell ...
Five cases of COVID-19 led to fatal treatment-emergent adverse events. All CRS cases resolved. One case of immune effector cell-associated neurotoxicity syndrome was reported. The CRS and ICANS cases ...
No Treatment Emergent Adverse Events Leading to Dose Reduction In Non-Hodgkin’s Lymphoma, Cemsidomide Monoth Much of the East Coast was in for a polar reprieve. But that warm-up comes with a price: ...
An investigational therapy for post-traumatic stress disorder (PTSD) improved symptom severity as soon as one month into a 12 ...
Scemblix resulted in better outcomes and fewer side effects compared to standard tyrosine kinase inhibitor therapies in ...
An expanded analysis from the phase 3 CEPHEUS trial showed that daratumumab plus VRd improved MRD responses as well as ...
Agios Pharmaceuticals (AGIO) presented positive results from the Phase 3 ENERGIZE-T study investigating mitapivat, an oral, small molecule PK ...
(MRD) testing achieved MRD negativity in MajesTEC-5 as induction therapy and MajesTEC-4 as maintenance therapy1,2 BEERSE, BELGIUM, Dec. 08, 2024 (GLOBE NEWSWIRE) -- Janssen-Cilag International NV, a ...